Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy

Publisher： Karger

E-ISSN： 1423-0232|64|4|300-305

ISSN： 0030-2414

Source： Oncology, Vol.64, Iss.4, 2003-05, pp. : 300-305

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Feasibility of Tri-Weekly Docetaxel-Based Chemotherapy for Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer

By  

Urologia Internationalis, Vol. 87, Iss. 3, 2011-08 ,pp. : 263-269

Karger

Access to resources Recommend Favorite

Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

By Yasufuku Tomihiko   Shigemura Katsumi   Matsumoto Osamu   Arakawa Soichi   Fujisawa Masato  

Journal of Infection and Chemotherapy, Vol. 16, Iss. 3, 2010-06 ,pp. : 200-205

Springer Publishing Company

Access to resources Recommend Favorite

Prostate-Specific Antigen Levels and Prognosis in Patients with Hormone-Refractory Prostate Cancer Treated with Low-Dose Dexamethasone

By  

Urologia Internationalis, Vol. 68, Iss. 1, 2002-01 ,pp. : 10-15

Karger

Access to resources Recommend Favorite

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

By  

THE PROSTATE, Vol. 75, Iss. 8, 2015-06 ,pp. : 836-844

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 237-242

Karger

Access to resources Recommend Favorite